Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1
monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK)
immunotherapy combined with hyperthermia in advanced malignant mesothelioma
patients.Furthermore,to characterize response to therapy,the investigators intent to explore
the predictive biomarker for this regimen.